Premium
The treatment of lymphoblastic lymphoma with antithymocyte globulin
Author(s) -
Wong K. K.,
Sweet Donald L.,
Variakojis Daina
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820701)50:1<57::aid-cncr2820500112>3.0.co;2-q
Subject(s) - medicine , prednisone , vincristine , lymphoblastic lymphoma , lymphoma , chemotherapy , premedication , cyclophosphamide , toxicity , t cell lymphoma , gastroenterology , surgery , immunology , t cell , immune system
A 20‐year‐old man with previously treated lymphoblastic lymphoma, a known T‐cell disorder, developed progressive disease despite intensive combination chemotherapy with doxorubicin, vincristine, and prednisone. He was subsequently treated with a 21‐day course of intravenous antithymocyte globulin at a dose of approximately 15mg/kg per day. This resulted in a marked reduction in lymphadenopathy as determined by physical examination and chest X‐ray. Toxicity was limited to minor pruritis which resolved with diphenyldramine and hydrocortisone premedication. Cancer 50:57–61, 1982.